News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
603,997 Results
Type
Article (64640)
Company Profile (132)
Press Release (539215)
Multimedia
Podcasts (135)
Webinars (21)
Section
Business (159818)
Career Advice (2509)
Deals (28806)
Drug Delivery (136)
Drug Development (73048)
Employer Resources (160)
FDA (16226)
Job Trends (12739)
News (285198)
Policy (30637)
Tag
Academia (2836)
Academic (1)
Accelerated approval (25)
Adcomms (35)
Allergies (127)
Alliances (39716)
ALS (159)
Alzheimer's disease (1692)
Antibody-drug conjugate (ADC) (269)
Approvals (16300)
Artificial intelligence (460)
Autoimmune disease (123)
Automation (27)
Bankruptcy (318)
Best Places to Work (9784)
BIOSECURE Act (23)
Biosimilars (177)
Biotechnology (83)
Bladder cancer (144)
Brain cancer (54)
Breast cancer (554)
Cancer (4246)
Cardiovascular disease (375)
Career advice (2126)
Career pathing (38)
CAR-T (252)
CDC (59)
Cell therapy (680)
Cervical cancer (33)
Clinical research (61621)
Collaboration (1327)
Company closure (4)
Compensation (1023)
Complete response letters (64)
COVID-19 (2780)
CRISPR (85)
C-suite (681)
Cystic fibrosis (136)
Data (5379)
Decentralized trials (2)
Denatured (33)
Depression (125)
Diabetes (456)
Diagnostics (5807)
Digital health (32)
Diversity (8)
Diversity, equity & inclusion (43)
Drug discovery (195)
Drug pricing (200)
Drug shortages (33)
Duchenne muscular dystrophy (217)
Earnings (62814)
Editorial (60)
Employer branding (21)
Employer resources (144)
Events (85689)
Executive appointments (927)
FDA (18920)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (17)
Funding (1221)
Gene editing (185)
Generative AI (40)
Gene therapy (561)
GLP-1 (1016)
Government (4325)
Grass and pollen (8)
Guidances (369)
Healthcare (16217)
HIV (48)
Huntington's disease (43)
IgA nephropathy (79)
Immunology and inflammation (261)
Immuno-oncology (35)
Indications (68)
Infectious disease (3021)
Inflammatory bowel disease (179)
Inflation Reduction Act (13)
Influenza (98)
Intellectual property (202)
Interviews (464)
IPO (14344)
IRA (56)
Job creations (3273)
Job search strategy (1752)
Kidney cancer (16)
Labor market (75)
Layoffs (612)
Leadership (37)
Legal (7175)
Liver cancer (89)
Longevity (11)
Lung cancer (584)
Lymphoma (338)
Machine learning (37)
Management (53)
Manufacturing (631)
MASH (157)
Medical device (12162)
Medtech (12194)
Mergers & acquisitions (15357)
Metabolic disorders (1206)
Multiple sclerosis (133)
NASH (22)
Neurodegenerative disease (292)
Neuropsychiatric disorders (79)
Neuroscience (2782)
NextGen: Class of 2025 (5449)
Non-profit (3796)
Now hiring (29)
Obesity (588)
Opinion (269)
Ovarian cancer (140)
Pain (172)
Pancreatic cancer (182)
Parkinson's disease (254)
Partnered (26)
Patents (433)
Patient recruitment (361)
Peanut (55)
People (52688)
Pharmaceutical (33)
Pharmacy benefit managers (29)
Phase I (18604)
Phase II (26773)
Phase III (21344)
Pipeline (3579)
Policy (310)
Postmarket research (2555)
Preclinical (8073)
Press Release (45)
Prostate cancer (216)
Psychedelics (49)
Radiopharmaceuticals (238)
Rare diseases (757)
Real estate (4745)
Recruiting (66)
Regulatory (23056)
Reports (39)
Research institute (2379)
Resumes & cover letters (411)
Rett syndrome (22)
RNA editing (13)
RSV (71)
Schizophrenia (141)
Series A (204)
Series B (160)
Service/supplier (9)
Sickle cell disease (96)
Special edition (24)
Spinal muscular atrophy (148)
Sponsored (44)
Startups (3046)
State (1)
Stomach cancer (19)
Supply chain (96)
Tariffs (97)
The Weekly (101)
Vaccines (1052)
Venture capital (75)
Weight loss (419)
Women's health (63)
Worklife (21)
Date
Last 7 days (612)
Last 30 days (2087)
Last 365 days (29071)
2025 (28258)
2024 (32464)
2023 (36417)
2022 (46902)
2021 (50586)
2020 (47996)
2019 (39372)
2018 (29709)
2017 (29838)
2016 (28403)
2015 (31176)
2014 (24713)
2013 (21588)
2012 (22877)
2011 (22954)
2010 (21201)
Location
Africa (789)
Alabama (70)
Alaska (7)
Arizona (227)
Arkansas (12)
Asia (35772)
Australia (6667)
California (9693)
Canada (2500)
China (842)
Colorado (384)
Connecticut (433)
Delaware (279)
Europe (87462)
Florida (1468)
Georgia (305)
Hawaii (3)
Idaho (46)
Illinois (706)
India (44)
Indiana (412)
Iowa (21)
Japan (346)
Kansas (106)
Kentucky (27)
Louisiana (20)
Maine (73)
Maryland (1254)
Massachusetts (7075)
Michigan (254)
Minnesota (530)
Mississippi (5)
Missouri (111)
Montana (14)
Nebraska (20)
Nevada (105)
New Hampshire (63)
New Jersey (2658)
New Mexico (19)
New York (2570)
North Carolina (1302)
North Dakota (9)
Northern California (4713)
Ohio (272)
Oklahoma (15)
Oregon (31)
Pennsylvania (1906)
Puerto Rico (14)
Rhode Island (32)
South America (1141)
South Carolina (57)
South Dakota (1)
Southern California (3758)
Tennessee (143)
Texas (1453)
United States (34436)
Utah (252)
Virginia (228)
Washington D.C. (73)
Washington State (774)
West Virginia (4)
Wisconsin (92)
Wyoming (1)
603,997 Results for "queen s university".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Celerion Expands UK Phase 1 Clinical Research Operations With New Agreement to Relocate to Queen’s University Belfast’s iREACH Health – Clinical Research Innovation Center
February 19, 2025
·
2 min read
Business
Aviceda Therapeutics Announces Strategic Partnership with Queen’s University Belfast (QUB)
Aviceda is partnering with world-renowned scientist Professor Christopher Scott and his teams at the Patrick G. Johnson Centre for Cancer Research at Queen’s University Belfast to spearhead development of the next generation of glyco-immune therapeutics.
April 10, 2023
·
5 min read
TC BioPharm Announces Grant Funding in Collaboration with Queen Mary University of London (QMUL)
TC BioPharm PLC is proud to announce it has entered into a collaboration agreement with Queen Mary University of London to research the therapeutic potential of gamma-delta T cells for the treatment of mucosal infections.
September 5, 2023
·
4 min read
Press Releases
Sequana Medical Announces U.S. Commercial alfapump® Implantations at University of Pennsylvania
December 11, 2025
·
8 min read
Biomind Labs and Queen’s University of Belfast Receive Controlled Substances License to Commence the Production of a Novel Transdermal Drug Delivery System
Biomind Labs and Queen’s University of Belfast Receive Controlled Substances License to Commence the Production of a Novel Transdermal Drug Delivery System.
September 27, 2022
·
7 min read
Parkinson’s disease
AC Immune’s Parkinson’s Immunotherapy Appears to Slow Disease Progression
In a first for the Parkinson’s field, AC Immune’s immunotherapy has stabilized key biomarkers that suggest an effect on the disease’s course.
December 11, 2025
·
1 min read
·
Annalee Armstrong
Press Releases
Red Queen Therapeutics Announces Expanded Licensing Agreement, Progress in Its Pan-Influenza Program
December 3, 2024
·
4 min read
Press Releases
Hemostemix Presents ACP-01 Data at University of Florida Grand Rounds: Highlights Strong Safety, Functional Gains, and Florida Access Pathway
Session led by neurosurgeon Dr. Fraser Henderson and Hemostemix CEO Thomas Smeenk for the University of Florida’s Department of Surgery, Division of Vascular Surgery & Endovascular Therapy (Gainesville)
November 13, 2025
·
10 min read
Press Releases
IonQ and the University of Washington Simulate Process Linked To The Universe’s Matter-Antimatter Imbalance
June 25, 2025
·
7 min read
Business
Envisagenics, Cancer Research Horizons, and Queen Mary University of London Announce Strategic Collaboration Agreement
Envisagenics , an Artificial Intelligence (“AI”)-driven biotechnology company that delivers therapies for RNA splicing diseases, today announced a research collaboration agreement with Cancer Research Horizons, Cancer Research UK’s innovation engine, and Queen Mary University of London.
December 13, 2022
·
5 min read
1 of 60,400
Next
